



Weill Cornell Medical College in Qatar



FONDAZIONE GIOVANNI LORENZINI MILAN, ITALY  GIOVANNI LORENZINI MEDICAL FOUNDATION HOUSTON, TX, USA

DALM **XVII** International Symposium

Diabetes, Obesity & the Metabolic Syndrome

**FINAL PROGRAM
AND
ABSTRACT BOOK**



ADDRESS FROM THE CHAIRPERSONS

Dear Colleague:

We are delighted to welcome you to Doha, Qatar for the **XVII International DALM Symposium on Diabetes, Obesity, and the Metabolic Syndrome**.

For the first time since the inception of the DALM symposia in 1960, the conference will take place in Doha, Qatar, instead of in the United States or Italy.

DALM 2011 is hosted by the Weill Cornell Medical College in Qatar, the first medical school in the country; the Qatar Foundation, a private non-profit organization established by His Highness, the Emir of the State of Qatar; and the Giovanni Lorenzini Medical Foundation, a non-profit organization based in Milan, Italy and Houston, Texas.

Together we are working to build biomedical research capacity in Qatar and to address significant public health challenges—obesity, diabetes, and cardiovascular disease foremost among them—currently facing the country and the region.

An energy-rich nation seeking to develop a knowledge-based economy, Qatar is poised to become a leader in education, research, and technology development within the Middle East.

At the same time, however, rapid economic growth and major shifts in lifestyle patterns have led to extremely high rates of diabetes, obesity, and metabolic syndrome in Qatar and many other nations in the Middle East and North Africa region.

Over the next few days, a faculty that includes internationally renowned clinicians and investigators will discuss the latest findings in the field, as well as cutting-edge strategies for prevention, diagnosis, and treatment. We hope that you find the symposium informative and stimulating and that you enjoy your stay in Qatar.

Sincerely,



Antonio M. Gotto

Antonio M. Gotto, Jr.

Weill Cornell Medical College
New York, NY



Rodolfo Paoletti

Rodolfo Paoletti

Giovanni Lorenzini
Medical Foundation
Milan, Italy and Houston, TX



J. Sheikh

Javid Sheikh

Weill Cornell Medical College
in Qatar
Doha, Qatar



Chairpersons: Antonio M. Gotto, Jr. (USA) – Rodolfo Paoletti (Italy) – Javaid Sheikh (Qatar)

International Program Committee: CM Ballantyne (USA) – AL Catapano (Italy) – RG Crystal (USA) – M Davidson (USA) – SM Sadikot (India)

Local Planning Committee: A Al-Ani (Qatar) – A Al Hamaq (Qatar) – JM Al Suwaidi (Qatar) – AA Gehani (Qatar) – AA Jayyousi (Qatar) – MA Zirrie (Qatar)

INTERNATIONAL ADVISORY BOARD

A Adlouni (Morocco) – OS Al-Attas (Saudi Arabia) – BJ Ansell (USA) – G Assmann (Germany) – L Badimon (Spain) – PJ Barter (Australia) – J Betteridge (UK) – AJB Brady (UK) – WV Brown (USA) – PK Deedwania (USA) – R Carmena (Spain) – A Corsini (Italy) – S Del Prato (Italy) – V Di Marzo (Italy) – RH Eckel (USA) – M Farnier (France) – JC Fruchart (France) – HN Ginsberg (USA) – H Greten (Germany) – SM Grundy (USA) – P Hildebrandt (Denmark) – CR Kahn (USA) – T Kita (Japan) – W Koenig (Germany) – E Leitersdorf (USA) – G Mancia (Italy) – N Marx (Germany) – B Masri (USA) – Y Matsuzawa (Japan) – FX Pi-Sunyer (USA) – PM Ridker (USA) – F Rubino (USA) – N Sarrafzadegan (Iran) – EJ Schaefer (USA) – PK Shah (USA) – CR Sirtori (Italy) – A Sussekov (Russia) – A Tall (USA) – MR Taskinen (Finland) – AA Tavassoli (Iran) – L Tokgözoğlu (Turkey) – E Tremoli (Italy) – J Tuomilehto (Finland) – TST Willing (Philippines) – L Van Gaal (Belgium) – JL Zamorano (Spain) – D Zhao (PR China)

SCIENTIFIC-ORGANIZING SECRETARIATS:

DALM 2011
Giovanni Lorenzini
Medical Foundation

6535 Fannin, MS A-601
Houston, TX 77030, USA
Phone: +1 713-797-0401

Fax: +1 713-796-8853
Email: dalm@bcm.edu

DALM 2011
Fondazione Giovanni Lorenzini
Medical Science Foundation

Via A. Appiani, 7
20121 Milan, Italy
Phone: +39 02 29006267

Fax: +39 02 29007018
Email: dalm@lorenzinifoundation.org

www.dalm2011qatar.org

Hosted By:

Qatar Foundation

Weill Cornell Medical College in Qatar

FONDAZIONE GIOVANNI LORENZINI MILAN, ITALY | GIOVANNI LORENZINI MEDICAL FOUNDATION HOUSTON, TX, USA

Qatar Foundation

Weill Cornell Medical College in Qatar

Giovanni Lorenzini Medical Foundation

In association with:

Qatar Supreme Council of Health

مؤسسة حمد الطبية
Hamad Medical Corporation
HEALTH · EDUCATION · RESEARCH | صحة · تعليم · بحوث

الجمعية القطرية للسكري
Qatar Diabetes Association

INTERNATIONAL ATHEROSCLEROSIS SOCIETY

Qatar Supreme Council of Health

Hamad Medical Corporation

Qatar Diabetes Association

International Atherosclerosis Society

Official carrier:

QATAR AIRWAYS القطرية

Qatar Airways

Official hotel:

THE RITZ-CARLTON

Ritz-Carlton Doha

IN GRATEFUL APPRECIATION


The Organizing Committee gratefully acknowledges generous support from the following:



Qatar Foundation



KOWA



NewYork-Presbyterian



abcam



Mercodia



GENERAL SYMPOSIUM INFORMATION

LOCATION AND DATE OF THE SYMPOSIUM

The Symposium will take place in Doha, Qatar at the Ritz-Carlton, Doha on March 14-16, 2011.

Ritz-Carlton, Doha
West Bay Lagoon
P.O. Box 23400
Doha, Qatar
Phone: +974 4484-8000
Fax: +974 4484-8484

All Symposium activities will take place in the conference and meeting spaces located off the main hotel lobby.

Lobby Level

Al Wosail Ballroom

Opening Ceremony
Scientific Sessions
Satellite Lunch Symposium

Al Mukhtasar Ballroom

Lunch

Al Wosail Foyer

Registration
Coffee Breaks
Exhibits
Poster Displays

Fateh Al-Khair

Speaker Ready Room

The Opening Ceremony, all DALM 2011 Scientific Sessions, and a lunchtime Satellite Symposium (March 15) will take place in the Al Wosail Ballroom. Please consult the Hotel Floor Plan on page 16 for room location details.

SECRETARIAT AND REGISTRATION DESK

The following services are available at the Secretariat and Registration Desk:

Registration

(pre-registrations and on-site registrations)

Secretariat

Invited Speakers Desk
CME Credits

Information

Lost & Found

Open Hours

Monday, March 14	2:00 pm – 7:30 pm
Tuesday, March 15	7:30 am – 6:30 pm
Wednesday, March 16	7:30 am – 5:30 pm

REGISTRATION

Only registered participants may attend the Scientific Sessions and Social Events offered by the Symposium. The late enrollment fee (from March 1 and on-site) will be charged if the registration form was received without payment.

The registration fees for the Symposium from March 1 and on-site are as follows (all amounts given in US Dollars):

Physicians and Scientists	US \$ 630
Medical Students/Residents*	US \$ 300
WCMC-Q Medical Students*	US \$ 0
Nurses, dietitians, psychologists*	US \$ 420
HMC Nurses*	US \$ 50

** Medical Student/Resident and Nurse/Dietitian/ Psychologist registration fees will be granted only to those who document their positions by providing a copy of their license/student ID or an official letter from the head of their Department or Institution.*

All registered participants are entitled to:

- Attend all Scientific Sessions and Satellite Symposium
- Attend the Opening Ceremony
- Attend the Exhibits and the Poster Viewing and Discussions
- Receive Final Program and Abstract Book
- Coffee Breaks and Lunches (March 15 and 16)

SATELLITE SYMPOSIUM

The lunchtime Satellite Symposium on March 15 is open to all participants. Seating is limited and determined on a first-come, first-served basis.

PRESS REGISTRATION

Working press from newspapers, magazines, radio, television, and medical publications will receive complimentary registration, provided that they submit a copy of their press credentials along with the registration form.

PRIVACY LAW

(FOR ITALIAN PARTICIPANTS)

Personal data will be handled exclusively by Fondazione Giovanni Lorenzini Medical Science Foundation according to the Italian Law 675/96 and law decree 196/2003.

CERTIFICATE OF ATTENDANCE

A Certificate of Attendance is available, upon request, from the Registration Desk at the end of the Symposium.

EMERGENCIES

To prepare for the unlikely event of a fire or other emergency requiring rapid departure, participants are encouraged to locate all exit doors and routes upon entering any room. In the case of an emergency requiring fire, ambulance, or police assistance, dial 999 on your cell phone.

LANGUAGE

The working language of the Symposium is English. Simultaneous translation in Arabic will be provided.

INTERNET AND COMPUTER ACCESS

Wireless internet access is available in the Al Wosail and Al Mukhtasar ballrooms. A computer kiosk is also available in the Al Wosail foyer.

BADGES

The official badge must be worn for admission to all Scientific Sessions and other activities of the Symposium.

SYMPOSIUM ATTIRE

Business attire is welcome for the Symposium.

COFFEE BREAKS

Early-Morning, Mid-Morning, and Mid-Afternoon Coffee Breaks will be offered to all registered participants in the foyer outside the Al Wosail ballroom on March 15 and 16.

LUNCH

Lunches will be offered to all registered participants in the Al Mukhtasar ballroom on March 15 and 16. Lunch will also be served during the Satellite Symposium on March 15 in the Al Wosail ballroom.

DINNER

Dinners are on your own. A list of nearby restaurants is provided in your registration materials.

EXHIBITS

During the Symposium, exhibits of pharmaceutical and medical technology suppliers and of academic/medical institutions in Qatar will be held in the foyer outside the Al Wosail ballroom. See page 17-18 for a list of exhibitors and the open and close times for each day.

SLIDE LIBRARY

A Slide Library of key selected presentations will be available after the Symposium at:
www.dalm2011qatar.org and
www.lorenzinifoundation.org

SYMPOSIUM WEBSITE

The home page for the DALM 2011 Symposium is located at:

www.dalm2011qatar.org

MESSAGES, MAIL, AND FAX

During the Symposium, correspondence and messages may be transmitted to Symposium participants who are guests at the hotel as follows:

(Insert Symposium participant's name here) --
GUEST

c/o Ritz-Carlton, Doha
P.O. Box 23400
Doha, Qatar
Phone: +974 4484-8000
Fax: +974 4484-8484

PROGRAM INFORMATION AND MESSAGE BOARD

A Program Information/Message Board is located in the registration area in the foyer outside the Al Wosail ballroom, where any last-minute program changes and other essential information will be posted. Participants are kindly asked to check this board frequently.

PERSONAL BELONGINGS

Please exercise adequate precautionary measures to safeguard your personal possessions. The Hotel, the Scientific-Organizing Secretariat, the Giovanni Lorenzini Medical Foundation, and the Weill Cornell Medical College in Qatar are not responsible for loss of any items. Safety deposit boxes are available at the Hotel's Front Desk and are also located in individual guest rooms.

PERSONAL INSURANCE COVERAGE

Registration for the Symposium implies that the delegate agrees that the Scientific-Organizing Secretariat, the Giovanni Lorenzini Medical Foundation, and the Weill Cornell Medical College in Qatar do not assume any liability or responsibility whatsoever. Symposium delegates are requested to make their own arrangements for medical, travel, and personal insurance.

CELLULAR PHONES, BEEPERS, AND ELECTRONIC DEVICES

In consideration of fellow participants, it is requested that all cell phones, pagers, and other electronic devices be turned off or set to silent mode during all Scientific Sessions to avoid disruption.

CANCELLATION OF THE MEETING

The Giovanni Lorenzini Medical Foundation/ Fondazione Giovanni Lorenzini Medical Science Foundation and the Weill Cornell Medical College in Qatar reserve the right, in their sole discretion, to unilaterally terminate the Symposium. In the unlikely event that the XVII International Symposium on Drugs Affecting Lipid Metabolism: Diabetes, Obesity, and the Metabolic Syndrome is abbreviated or cancelled for any reason whatsoever, the registrant and/or any funding/sponsoring organization hereby agrees to waive any claim against the Giovanni Lorenzini Medical Foundation/ Fondazione Giovanni Lorenzini Medical Science Foundation and the Weill Cornell Medical College in Qatar for damages or compensation including, but not limited to, fees for registration, housing, airfare, and incidental charges.



GENERAL HOTEL AND CITY INFORMATION

RITZ-CARLTON DOHA CHECK IN / CHECK OUT TIMES

Guest rooms are available for check-in after 3:00 pm. Check out is by 12:00 pm. Participants can check out of their guest room and store their luggage with the Hotel's Bell Stand for a later departure that day from the Hotel.

BANK AND CURRENCY EXCHANGE

Transactions are conducted using the Qatari Riyal (QR), which is divided into 100 dirhams. Most major establishments accept major credit cards. The exchange rate is fixed at US \$1 = QR 3.64. A passport is required for currency exchange. The Hotel's Front Desk provides currency exchange services, and an ATM machine is located in the Hotel Lobby. In addition, a branch of Qatar National Bank is located on the Lower Lobby Level and can be contacted by calling +974 4426-8402. Hours of operation are Sunday through Thursday, 9:00 am–3:30 pm. In general, banks in Qatar are open from 7:30 am to 1 pm, although some branches, particularly those located in shopping centers, are also open in the evenings.

BUSINESS CENTER

A fully staffed Business Center is located on the Lobby Level next to the Concierge Desk. Hours of operation are Saturday through Thursday, 8:00 am–9:00 pm. For information on all services provided, please contact the Business Center by calling Ext. 8363 on a Hotel house phone.

TRANSPORTATION

The Hotel's Concierge Desk in the Hotel Lobby can provide transportation assistance. Taxi service is readily available from the airport. There is one taxi company currently operating in Doha, Mowasalat-Karwa (green taxis), which can be contacted by calling +974 4458-8888. Meters start at QR 4 (US \$1.10) and run at QR 1-2 (US \$0.27-0.55) per kilometer. The Ritz-Carlton is located 40 kilometers and approximately 25 minutes away from the airport.

A complimentary hotel shuttle is available for hotel guests from 7:00 am–10:00 am and from 3:00 pm–7:00 pm on weekdays, and from 11:30 am–6:00 pm on weekends. The shuttle stops at various points in the City Center district. Reservations are required and can be made by contacting the Concierge at +974 4484-8118 or Ext. 8119/8118 on a Hotel house phone, or by visiting the Concierge Desk in the Hotel lobby.

HOTEL PARKING

Self-parking and complimentary valet parking are available at the Hotel.

HOTEL ACCESSIBILITY

All hotel areas are wheelchair accessible, either by elevator or ramp. Complimentary valet parking is available.

TOURS, SIGHTSEEING, AND RESTAURANT

The Hotel's Concierge Desk in the Hotel Lobby can assist you with planning and making reservations for your free-time activities. A list of nearby restaurants is provided in your registration materials. The Concierge Desk can be contacted at Ext. 8119 or 8118 on a Hotel house phone, or by calling +974 4484-8118.

HOURS OF WORK/ BUSINESS

The workweek in Qatar typically runs from Sunday to Thursday, with Friday (holy day for Muslims) and Saturday off. Government offices are open between 6 am–2 pm. Commercial offices are generally open from 7:30 am–12:00 pm and from 3:30 pm–7:30 pm, although specific hours can vary. Major shopping malls are usually open from 10:00 am–10:00 pm, but the majority are closed Friday mornings.

LANGUAGE

The national language of Qatar is Arabic. English is also commonly spoken in Doha.

ATTIRE

Cotton or lightweight clothing is suitable for daywear. Proper evening attire is recommended when dining in restaurants. Skirts or shorts above the knee should be avoided, as should sleeveless tops that expose the shoulders or upper arms. Very tight or revealing clothing should also be avoided.

PHONE

The country code for Qatar is 974, and there are no city codes. International calls are made by first dialing 00. For local directory assistance, call 180.

ELECTRICITY

The electrical supply operates at 220-240 volts and 50 Hz. There are two types of electrical outlets: Type G (British, fits 3 rectangular pins) and Type D (Old British, fits 3 round pins). Adapters are available in most supermarkets and corner stores.

GRATUITIES

An average restaurant tip is 10%, although some restaurants automatically add a 10% service charge to the bill. Tipping of bellmen, hotel doormen, tour guides, etc. is done at an individual's discretion. Tipping is customary for taxis.

SYMPOSIUM PROGRAM INFORMATION

The official DALM 2011 Symposium badge must be worn for admission to all Scientific Sessions and other activities of the Symposium.

The Scientific Program includes Keynote Lectures, State-of-the-Art Lectures, Case Study Roundtables, Roundtable Discussions, Oral Presentations, and Poster Sessions of Contributed Papers.

SCIENTIFIC SESSION SCHEDULE

The Scientific Sessions are scheduled as follows:

Monday, March 14	5:00 pm – 7:00 pm
Tuesday, March 15	8:30 am – 6:20 pm
Wednesday, March 16	8:30 am – 5:25 pm

SPEAKER INFORMATION

Presenters and Chairs should note the following information.

Rules for Chairpersons

Every effort must be made to adhere strictly to the time schedule of the Scientific Sessions. Chairpersons are asked to interrupt speakers if they exceed the allocated time for their presentation.

Oral Presentations

Audiovisual

All audiovisual needs should have been pre-arranged with the Scientific-Organizing Secretariat. For on-site assistance, please contact the Secretariat Desk.

PowerPoint presentations will be accommodated with an LCD/data projection system. The lecture room will be networked into a central communications system that will electronically “deliver” each speaker’s computer-based presentation. Speakers should scan their presentations for viruses, preview their slide files, and download their presentation onto the networked system in the Speaker Ready Room (Fateh Al-Khair) the day before their presentation, but no later than 2 hours before the start of their session.

Speaker Ready Room

Speakers should report to the Speaker Ready Room the day before their presentation is scheduled, but no later than 2 hours before the start of their session. The staff in the Speaker Ready Room will assist speakers with finalizing their visuals and downloading their presentations.

The Speaker Ready Room is located in the Fateh Al-Khair conference room. An audiovisual technician is available to assist oral presenters during the following hours:

Monday, March 14	3:00 pm – 8:00 pm
Tuesday, March 15	7:00 am – 6:30 pm
Wednesday, March 16	7:00 am – 4:30 pm

For any other assistance, please contact the Secretariat Desk.

Posters

Poster Numbers and Location

All Posters will be displayed in the Al Wosail foyer. The poster board number corresponding to the poster abstract listing in the Final Program will be posted on the top of each poster board. Authors must use the poster board with their abstract number.

Poster Mounting

Poster authors must mount their poster presentations according to the following schedule:

Monday, March 14	2:00 pm – 5:00 pm
Tuesday, March 15	7:30 am – 8:30 pm

Poster Display

Poster Display is for the duration of the Symposium. Poster Displays will be open during the following hours in the foyer outside the Al Wosail ballroom:

Monday, March 14	5:00 pm – 7:00 pm
Tuesday, March 15	8:30 am – 6:20 pm
Wednesday, March 16	8:30 am – 5:25 pm

Poster Assistance

A Poster Assistant will be present to provide any information or help the author may need during Poster Mounting.

Poster Discussions and Author Attendance

At least one author per Poster Presentation is required to attend his or her Poster Discussion during the scheduled Poster Discussion times:

Poster Discussion Group A (#40-92):

Tuesday, March 15	10:15 am – 10:45 am
	4:00 pm – 4:30 pm

Poster Discussion Group B (#93-144):


Wednesday, March 16	1:00 pm – 2:00 pm
----------------------------	-------------------

Facilities for slide projection are not available at the site of the Poster Presentation. Photocopies may be made from the reduced image of the Poster, and any additional materials may be distributed by the author(s) at the Poster Presentation site.

Poster Removal

All posters must be completely removed at the end of the scientific sessions on Wednesday, March 16, between 5:30 pm and 6:30 pm. The Organizers are not responsible for any items, including Posters, left in the hotel after this time.

RITZ-CARLTON FLOORPLAN



Floorplan of Function Areas

EXHIBITS INFORMATION

Scientific Exhibits

Exhibits of pharmaceutical and medical technology suppliers and of academic/medical institutions in Qatar will be held in the foyer outside the Al Wosail ballroom.

The Exhibits are open during the following hours:

Monday, March 14 | 2:00 pm – 6:00 pm

Tuesday, March 15 | 8:30 am – 6:00 pm

Wednesday, March 16 | 8:30 am – 6:00 pm

LIST OF EXHIBITORS

Abcam

All the best for Cardiovascular research at Abcam. Abcam is able to deliver a comprehensive portfolio of all the very best and most up to date cardiovascular antibodies and related products. A leading online provider of primary and secondary antibodies to researchers worldwide, Abcam's diverse catalog of over 68,000 antibodies includes cutting edge tools for neuroscience, chromatin-nuclear signaling, stem cells, immunology and cancer as well as cardio research. We also provide proteins, ELISA, lysates and slides.
www.abcam.com/cardio

Giovanni Lorenzini Medical Science Foundation
The mission of the Giovanni Lorenzini Medical Foundation is to transfer the most recent developments and results in experimental science to clinical and applied research, to be used to update and inform the medical community worldwide with the result of enhancing patient care. The Lorenzini Foundation is located in Milan, Italy and Houston, TX, USA.
Please refer to the Foundation website for more information: www.lorenzinifoundation.org

Hamad Medical Corporation

Hamad Medical Corporation is the premier public healthcare provider in Doha, Qatar. It comprises a network of specialized hospitals—Hamad General Hospital, Rumailah Hospital, Women's Hospital, Al Amal Hospital (specializing in cancer treatment) and Al Khor Hospital (a local community hospital) — with more hospitals under development. HMC is mandated to pursue excellence in Health, Education and Research to provide high quality care to all patients.

Kowa

Kowa Company, Ltd. has grown into a global company on several business fields of pharmaceutical products, optical devices, textiles, machinery and construction materials. Our pharmaceutical focus is primarily on the therapeutic area of lifestyle-related diseases, seeking novel innovative drugs through the R&D activities of drug discovery, formulation development and neo-generics.

Mercodia

Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies to large pre-clinical and clinical phase trials. The company was founded in 1991 and is today a world-leading supplier of products to all major international markets. More than ninety percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world. Mercodia provides a professional scientific support system by collaborating with customers and institutions worldwide to develop novel applications for existing products and unique diagnostics for emerging markets.

NewYork-Presbyterian Hospital

NewYork-Presbyterian Hospital is one of the most comprehensive university hospitals in the world, with leading specialists in every field of medicine. We are composed of two renowned medical centers, NewYork-Presbyterian Hospital/Columbia University Medical Center and NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and affiliated with two Ivy League medical institutions, Columbia University College of Physicians and Surgeons and Weill Cornell Medical College.

Qatar Diabetes Association

The Qatar Diabetes Association was established by His Highness the Emir Sheikh Hamad Bin Khalifa Al-Thani. Overseen by Her Highness Sheikha Mozah Bint Nasser al-Missned, the association provides useful and up to date information that will help patients and their families to understand the reality of diabetes, prevention strategies, treatment options and lifestyle suggestions. Components of the organization include a scientific committee, education center, volunteer center, youth camps, events and conferences.

Qatar Foundation

Qatar Foundation is a private, non-profit organization established by His Highness the Emir Sheikh Hamad Bin Khalifa Al-Thani to help Qatar become an advanced knowledge-based society. Chaired by Her Highness Sheikha Mozah Bint Nasser al-Missned, it supports education, research and community development to transform Qatar, improving the standard of living for all its people while preserving its culture and traditions.

Supreme Council of Health

Under the guidance of His Highness the Emir Sheikh Hamad Bin Khalifa Al-Thani, the Supreme Council of Health was established to oversee health care reform in Qatar. It relies on evidence-based policies that seek to improve the health and wellbeing of individuals, their families and the community at large. Change is continuously measured against established objectives to be certain progress is being achieved.

CONTINUING MEDICAL EDUCATION (CME)

CME Course Director

Javid I. Sheikh, MD, Weill Cornell Medical College in Qatar (Doha, Qatar)

Statement of Need

Rapid economic growth, accompanied by major shifts in lifestyle patterns, has increased the global burden of diabetes and other cardiometabolic disorders, particularly within countries in the Middle East. According to the International Diabetes Federation, six countries in the Middle East and North Africa region rank among the world's 10 highest for diabetes prevalence: Bahrain, Egypt, Kuwait, Oman, Saudi Arabia, and the United Arab Emirates. In Qatar, the prevalence of diabetes is 15.4%, with 34.6% of adult men and 45.3% of adult women estimated to be obese by the International Obesity Taskforce. This international symposium will facilitate open discussion and peer-to-peer dialogue among health care providers and experts from both the Middle East and the larger global community, in order to address the mounting public health challenges of diabetes, obesity, and related cardiometabolic disorders. It will update practitioners and health organization representatives on the latest advances in prevention and treatment, with the aim of furthering the development of regionally and nationally specific programs for risk factor education and control. The conference will additionally provide a forum for cross-cultural scientific exchange in order to enhance our understanding of the genetic, ethnic, environmental, epidemiological, and sociocultural determinants of metabolic disease.

Target Audience

This symposium is designed for a multidisciplinary audience, particularly physicians and health care practitioners in the fields of cardiology, diabetology, endocrinology, epidemiology, family medicine, genetic medicine, geriatrics, internal medicine, lipidology, pediatrics, primary care, and public health. Basic scientists, clinical researchers, and representatives from health regulatory agencies and industry will also benefit from the scientific, clinical, and economic discussions during the conference.

Course Goals and Objectives

At the conclusion of this activity, participants should be able to:

- 1- Discuss the benefits of lifestyle and dietary modifications with patients with or at risk for diabetes, obesity, and the metabolic syndrome, with an increased awareness of issues surrounding compliance and adherence;
- 2- Recognize, diagnose, and treat lipid abnormalities in patients, in accordance with current guidelines regarding dietary, lifestyle, and pharmaceutical therapy;
- 3- Evaluate the efficacy, safety, and tolerability of various drugs for the treatment of diabetes, obesity, and cardiometabolic risk factors, in order to implement appropriately targeted treatment plans;
- 4- Assess international guidelines for the diagnosis, prevention, and treatment of diabetes, obesity, and metabolic syndrome in terms of their applicability within countries in the Middle East;
- 5- Discuss the economic and public health challenges surrounding diabetes, obesity, and metabolic syndrome in the Middle East, with the goal of developing country-specific strategies for prevention and treatment;
- 6- Apply current guidelines regarding the identification of patients at increased risk for cardiovascular disease and diabetes to clinical practice, for populations including women, children, and the elderly;
- 7- Discuss ongoing research on novel risk factors, emerging biomarkers, and genetic testing in terms of its future applicability in the Middle East.

Accreditation

The XVII International DALM Symposium on Diabetes, Obesity, and the Metabolic Syndrome was granted 13 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation

European Accreditation is granted by the EACCME in order to allow participants who attend the above-mentioned activity to validate their credits in their own country.

Accreditation Statement

The Giovanni Lorenzini Medical Foundation is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 'XVII International DALM Symposium on Diabetes, Obesity, and the Metabolic Syndrome' is designated for a maximum of 13 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA, www.ama-assn.org.

EACCME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Hamad Medical Corporation CME

This Symposium is also accredited for 15 CME points through the Hamad Medical Corporation in Qatar. These credits are recognized by the Royal College of Physicians and Surgeons of Canada.

Participants interested in receiving CME credits should inquire about the necessary application forms and questionnaires at the registration desk.

SCIENTIFIC PROGRAM

The Presenting Author is in bold face type.

Abstract # Ref: refers to abstracts listed following the Scientific Program schedule.

ADMISSION TO THE SCIENTIFIC SESSIONS IS RESERVED ONLY FOR PARTICIPANTS WEARING THE SYMPOSIUM BADGE

All Scientific Sessions are located in the Al Wosail ballroom.

5:00 pm – 7:00 pm

MONDAY, MARCH 14

Hour:

Abstract # Ref.

SESSION 1:

OPENING CEREMONY

Chairs:

Javaid I. Sheikh (Doha, Qatar)

Antonio M. Gotto, Jr. (New York, NY, USA)

Rodolfo Paoletti (Milan, Italy)

Welcome and Opening Remarks

5:00 pm – 6:00 pm

Javaid I. Sheikh

Weill Cornell Medical College in Qatar (Doha, Qatar)

Rodolfo Paoletti

Giovanni Lorenzini Medical Foundation (Milan, Italy)

Antonio M. Gotto, Jr.

Weill Cornell Medical College (New York, NY, USA)

Keynote Lectures

6:00 pm – 6:30 pm

A GLOBAL PERSPECTIVE ON CVD, DIABETES, AND OBESITY

Thomas A. Gaziano (Boston, MA, USA)

1

6:30 pm – 7:00 pm

REGIONAL AND ETHNIC PRONENESS TO DIABETES, OBESITY, AND THE METABOLIC SYNDROME

Mahmoud A. Zirie (Doha, Qatar)

2

7:00 pm

End of the session

8:30 am – 12:20 pm

TUESDAY, MARCH 15

Hour:

Abstract # Ref.

SESSION 2:

OVERWEIGHT AND OBESITY

Keynote Lecture

Chair: **Ronald G. Crystal** (New York, NY, USA)

8:30 am – 8:55 am

LEPTIN AND THE BIOLOGIC BASIS OF OBESITY

Jeffrey M. Friedman (New York, NY, USA)

3

Roundtable

THE MANAGEMENT OF THE OBESE PATIENT

Moderators:

Maryam Ebrahim Al Harmasi Al Hajeri (East Ruffaa, Bahrain)

Barbara V. Howard (Washington, DC, USA)

9:00 am – 9:15 am

THE DYSLIPIDEMIA OF OBESITY

Barbara V. Howard (Washington, DC, USA)

4

9:15 am – 9:30 am

THE HYPERTENSIVE OBESE PATIENT

Luc F. Van Gaal (Antwerp, Belgium)

5

9:30 am – 9:45 am

COGNITIVE FUNCTION IN NORMAL OLDER ADULTS: EFFECTS OF OBESITY, GENETICS, AND SLEEP APNEA

Jerome Yesavage (Stanford, CA, USA)

6

9:45 am – 10:15 am

PANEL DISCUSSION

Nadia N. Ghannam (Jeddah, Saudi Arabia)

Masoud Y. Al-Maskari (Muscat, Oman)

Ahmed A.R. Muhamad Al-Ani (Doha, Qatar)

10:15 am – 10:45 am

Coffee Break

Keynote Lecture

Chair: **M. John Chapman** (Paris, France)

10:45 am – 11:10 am

PERSONALIZED CARDIOVASCULAR MEDICINE

Gerd Assmann (Muenster, Germany)

7

Hour:

Abstract # Ref.

Roundtable

	PRIMARY PREVENTION IN PATIENTS WITH METABOLIC SYNDROME Moderators: Monira Al Arouj (Kuwait City, Kuwait) M. John Chapman (Paris, France)	
11:15 am – 11:30 am	LIPOPROTEIN (a) AS AN ATHEROTHROMBOGENIC RISK FACTOR IN CARDIOMETABOLIC DISEASE: THE EAS CONSENSUS M. John Chapman (Paris, France)	8
11:30 am – 11:45 am	RISK STRATIFICATION IN THE METABOLIC SYNDROME William B. Borden (New York, NY, USA)	9
11:45 am – 12:00 pm	PRIMARY PREVENTION IN PATIENTS WITH METABOLIC SYNDROME Michael Davidson (Chicago, IL, USA)	10
12:00 pm – 12:20 pm	PANEL DISCUSSION Mohamed A. Al-Lamki (Muscat, Oman) Amin Jayyousi (Doha, Qatar)	
12:20 pm	End of the Session	

Hour:

Abstract # Ref.

KOWA SATELLITE SYMPOSIUM

PITAVASTATIN: A NEW STATIN AND ITS ROLE IN METABOLIC SYNDROME

	Chair: Antonio M. Gotto, Jr. (New York, NY, USA)	
12:30 pm – 12:50 pm	METABOLIC SYNDROME: EPIDEMIOLOGY AND CHALLENGES Antonio M. Gotto, Jr. (New York, NY, USA)	11
12:50 pm – 1:10 pm	METABOLIC SYNDROME: LIPID MANAGEMENT IN THE CLINIC Ibrahim S. Salti (Beirut, Lebanon)	12
1:10 pm – 1:30 pm	PITAVASTATIN: FROM PHARMACOLOGY TO CLINICAL PRACTICE Michel Farnier (Dijon, France)	13
1:30 pm – 1:50 pm	STATINS IN THE TREATMENT OF DIABETES AND METABOLIC SYNDROME Koutaro Yokote (Chiba, Japan)	14
1:50 pm – 2:00 pm	CLOSING REMARKS Antonio M. Gotto, Jr. (New York, NY, USA)	
2:00 pm	End of the Session	

*Supported by an educational grant from **Kowa Pharmaceuticals**.*

The Satellite Symposium is open to all participants and is located in Al Wosail ballroom. Seating is limited and determined on a first-come, first-served basis.

2:15 pm – 6:20 pm

TUESDAY, MARCH 15

Hour:

Abstract # Ref.

**SESSION 3:
PRE-DIABETES AND DIABETES**

Keynote Lecture

Chair: **Antonio M. Gotto, Jr.** (New York, NY, USA)

2:15 pm – 2:40 pm SPECULATION ON THE EVOLUTIONARY ORIGINS AND PERSISTENCE OF THE METABOLIC SYNDROME: POSSIBLE APPLICATIONS TO CLINICAL CARE **Jesse Roth** (Whitestone, NY, USA) **15**

Case Study Roundtable

THE PATIENT WITH PRE-DIABETES

Moderators:

Masoud Y. Al-Maskari (Muscat, Oman)

Marja-Riitta Taskinen (Helsinki, Finland)

2:45 pm – 3:00 pm LIFESTYLE MODIFICATIONS TO PREVENT DIABETES: CURRENT STATUS OF SUCCESSFUL WORK **Jaakko Tuomilehto** (Helsinki, Finland) **16**

3:00 pm – 3:15 pm PHARMACOLOGICAL TREATMENT OF THE PRE-DIABETIC STATE **Rafael Carmena** (Valencia, Spain) **17**

3:15 pm – 3:30 pm IS A STATIN WARRANTED? **Antonio M. Gotto, Jr.** (New York, NY, USA) **18**

3:30 pm – 4:00 pm PANEL DISCUSSION **Ibrahim Naguib El Ebrashy** (Cairo, Egypt) **Mahmoud A. Zirie** (Doha, Qatar) **Abdulla Al-Hamaq** (Doha, Qatar)

4:00 pm – 4:30 pm Coffee Break

State-of-the-Art Lectures

NOVEL THERAPIES FOR METABOLIC SYNDROME, DYSLIPIDEMIA, AND OBESITY

Moderators:

Abdullah Ben Nakhi (Kuwait City, Kuwait)

Michael Davidson (Chicago, IL, USA)

4:30 pm – 4:50 pm CETP INHIBITORS **Philip Barter** (Sydney, Australia) **19**

4:50 pm – 5:10 pm MTP INHIBITORS **Michael Davidson** (Chicago, IL, USA) **20**

5:10 pm – 5:30 pm PPARs **Willa A. Hseuh** (Houston, TX, USA) **21**

5:30 pm – 5:50 pm BARIATRIC SURGERY **Francesco Rubino** (New York, NY, USA) **22**

5:50 pm – 6:10 pm ANTI-OBESITY THERAPIES **Louis J. Aronne** (New York, NY, USA) **23**

6:10 pm – 6:20 pm DISCUSSION

6:20 pm End of the Session

8:30 am – 11:15 am

WEDNESDAY, MARCH 16

Hour:

Abstract # Ref.

**SESSION 4:
LIPIDS AND CVD COMPLICATIONS**

Case Study Roundtable

PATIENTS WITH DIABETIC DYSLIPIDEMIA

Moderators:

Maryam Ebrahim Al Harmasi Al Hajeri (East Ruffaa, Bahrain)

Gerd Assmann (Muenster, Germany)

8:30 am – 8:45 am LOW HDL AND HIGH TG **Alberico L. Catapano** (Milan, Italy) **24**

8:45 am – 9:00 am FAMILIAL DYSLIPIDEMIA **W. Virgil Brown** (Atlanta, GA, USA) **25**

9:00 am – 9:15 am RESIDUAL CARDIOVASCULAR RISK IN STATIN-TREATED PATIENTS **Gerd Assmann** (Muenster, Germany) **26**

9:15 am – 9:35 am PANEL DISCUSSION **Jassim Al Suwaidi** (Doha, Qatar) **Abdurrazzak Gehani** (Doha, Qatar)

9:35 am – 10:05 am Coffee Break

Hour:

Abstract # Ref.

Keynote Lectures

GENETIC DYSLIPIDEMIAS: FOCUS ON THE MIDDLE EAST

Moderators:

Mohamed Abdullah Al-Lamki (Muscat, Oman)**Robert W. Mahley** (San Francisco, CA, USA)

10:05 am – 10:30 am MIDDLE EASTERN AND CENTRAL ASIAN GENETIC ANCESTRY IMPACTS PLASMA LIPIDS: LESSONS FROM THE TURKISH HEART STUDY **27**
Robert W. Mahley (San Francisco, CA, USA)

10:30 am – 10:55 am QATARI GENOMIC STRUCTURE, GENETIC VARIATION AND DISEASE RISK **28**
Ronald G. Crystal (New York, NY, USA)

10:55 am – 11:15 am DISCUSSION

11:15 am End of the Session

Hour:

Abstract # Ref.

SESSION 5:

SELECTED ORAL PRESENTATIONS

Chairs:

Alvin I. Mushlin (New York, NY, USA)**Rafael Carmena** (Valencia, Spain)

11:15 am – 11:30 am CARDIOVASCULAR COMPLICATION OF DIABETES IN QATAR **29**
Alvin I. Mushlin, Paul J. Christos, Hiam Chemaitelly, Laith J. Abu-Raddad (New York, NY, USA and Doha, Qatar)

11:30 am – 11:45 am SUSTAINED EFFECT OF LIPOPROTEIN LIPASE (LPL) GENE THERAPY ON CLINICAL EXPRESSION, CHYLOMICRON CLEARANCE AND ACYLGLYCEROL METABOLISM IN LPL DEFICIENCY **30**
Daniel Gaudet, Julie Methot, Yacine Loucif, Claude Gagné, Stephane Dery, Janneke de Wal, Jaap Twisk, Frederique Frisch, Diane Brisson, André Carpentier (Montreal, QC, Canada, Amsterdam, Netherlands, and Sherbrooke, QC, Canada)

11:45 am – 12:00 pm FTO POLYMORPHISM IS ASSOCIATED WITH DIABETES MELLITUS COMPLICATIONS **31**
Jaroslav A. Hubacek, Dana Dlouha, Vera Adamkova, Tereza Pelikanova (Prague, Czech Republic)

12:00 pm – 12:15 pm ROLE OF CNS IRS2 SIGNALING IN MEDIATING THE CHRONIC EFFECTS OF LEPTIN ON GLUCOSE REGULATION **32**
J. Nathan Freeman, Jussara M. do Carmo, **Ahmad H. Adi**, John E. Hall, Arthur C. Guyton, Alexandre A. da Silva (Jackson, MS, USA and Riyadh, Saudi Arabia)

12:15 pm – 12:30 pm APOE*3LEIDEN.CETP TRANSGENIC MICE AS MODEL FOR THE METABOLIC SYNDROME **33**
Anita M. van den Hoek, **José W.A. Van der Hoorn**, Annemarie CE Maas, Ria M. van den Hoogen, Anita van Nieuwkoop, Erik O. Offerman, Elsbet J. Pieterman, Louis M. Havekes, Hans M.G. Princen (Leiden, Netherlands)

12:30 pm End of the Session

**SESSION 6:
THERAPEUTIC GUIDELINES**

Keynote Lectures

INTERNATIONAL GUIDELINES

Moderators:

Ibrahim Naguib El Ebrashy (Cairo, Egypt)

Abdulrazzaq Al Madani (Dubai, United Arab Emirates)

Alberico L. Catapano (Milan, Italy)

2:00 pm – 2:25 pm	THE US GUIDELINES IN A GLOBAL CONTEXT W. Virgil Brown (Atlanta, GA, USA)	34
2:25 pm – 2:50 pm	EUROPEAN GUIDELINES IN A GLOBAL CONTEXT Marja-Riitta Taskinen (Helsinki, Finland)	35
2:50 pm – 3:15 pm	ASIAN GUIDELINES IN THE GLOBAL CONTEXT Mahmoud A. Zirie (Doha, Qatar)	36
3:15 pm – 3:35 pm	DISCUSSION	
3:35 pm – 4:05 pm	Coffee Break	

Overview and Discussion

CHALLENGES OF DIABETES, OBESITY, AND THE METABOLIC SYNDROME: IMPLEMENTING THERAPEUTIC STRATEGIES IN THE MIDDLE EAST

Moderators:

Antonio M. Gotto, Jr. (New York, NY, USA)

Javaid I. Sheikh (Doha, Qatar)

4:05 pm – 4:20 pm	CARDIOVASCULAR RISK REDUCTION IN DIABETES, HOW LOW SHOULD WE GO? Adel A. El-Sayed (Sohag, Egypt)	37
4:20 pm – 4:35 pm	CHALLENGES OF CHANGING THE HEALTH CARE SYSTEM TO MANAGE DIABETES AND METABOLIC SYNDROME Kazem Behbehani (Kuwait City, Kuwait)	38
4:35 pm – 4:50 pm	WOMEN AND DIABETES Abdulrazzaq Ali Al Madani (Dubai, United Arab Emirates)	39
4:50 pm – 5:10 pm	DISCUSSION	
5:10 pm – 5:25 pm	CLOSING REMARKS	
5:25 pm	End of the Symposium	

POSTER DISCUSSION GROUP A

Posters marked with YIA are competing for the Young Investigator Award.

Poster Display and Viewing:

Participants may view the Poster Display in the foyer outside the Al Mukhtasar ballroom as follows:

Monday, March 14	5:00 pm – 7:00 pm
Tuesday, March 15	8:30 am – 6:20 pm
Wednesday, March 16	8:30 am – 5:25 pm

Poster Discussion: One of the authors will be available at the poster site as follows:

Poster Discussion Group A (#40-92):	
Tuesday, March 15	10:15 am – 10:45 am 4:00 pm – 4:30 pm

POSTER DISCUSSION GROUP A

Abstract # Ref./
Poster Board #

FACTORS ASSOCIATED WITH FIBRATE-INDUCED CREATININE ELEVATION Ahmed Abbas , Shanath Ramachandran, Sanjay Saraf, Sud Ramachandran (Birmingham, United Kingdom)	40 YIA
SIGNIFICANT INCREASE IN HDL-C WITH FIBRATES IS ASSOCIATED WITH LOW PRE-TREATMENT HDL-C: FINDINGS FROM AN OUTPATIENT CLINIC SETTING Ahmed Abbas , Sanjay Saraf, Christina Jewkes, Alan Jones, Sud Ramachandran (Birmingham, United Kingdom)	41 YIA
MOLECULAR SIGNATURE OF HUMAN BROWN ADIPOCYTE-LIKE PAZ6 CELLS Mouaadh Abdelkarim , Virginia Takahashi, Smitha Kota, A. Donny Strosberg, Lotfi Chouchane (Doha, Qatar and Jupiter, FL, USA)	42
LATE ONSET HYPOGONADISM AND TYPE 2 DIABETES MELLITUS Mohamed Mostafa Arafa, Wael Zohdy, Samar Hassona Aboulsoud (Cairo, Egypt and Doha, Qatar)	43
THE CONSUMPTION OF ARGAN OIL INDUCES A MARKED LIPID LOWERING EFFECT IN NEVER-TREATED PATIENTS WITH DYSLIPIDEMIA Ahmed Adlouni , Mahmoud Yezid, Mariame El Messal, Mohamed Said El Kebbjaj, Abdelmjid Chraibi (Casablanca, Morocco and Rabat, Morocco)	44
PARAMETERS OF METABOLIC SYNDROME IN SUBJECTS UNDERGOING CORONARY ANGIOGRAM: CASE STUDY FROM A TERTIARY CARE HOSPITAL IN BANGLADESH Faria Afsana , Zafar Ahmed Latif, M. Maksumul Haq (Dhaka, Bangladesh)	45

POSTER DISCUSSION GROUP A

Abstract # Ref./
Poster Board #

- ENHANCED OXIDATIVE STRESS IN TYPE 2 DIABETES-LINKED
ATHEROTHROMBOSIS: INTRODUCING NEW GLYCEMIC CONTROL TARGET
Khaled Abdul-Aziz Ahmed (Ibb, Yemen) **46**
- DREAM & REALITY IN SLEEVE GASTRECTOMY
Amer Hashim Al Ani, Hussien Shamout, Awad Al Dumor, Monther Abu Reden,
Sallam Al Hanash (Amman, Jordan) **47**
- HOW TO IDENTIFY METABOLIC SYNDROME
Magdi Eid Nasr Al Osali (Muscat, Oman) **48**
- HYPOMAGNESEMIA IN OMANI TYPE 2 DIABETIC PATIENTS
Magdi Eid Nasr Al Osali (Muscat, Oman) **49**
- PREVENTION OF TYPE 2 DIABETES MELLITUS
Magdi Eid Nasr Al Osali (Muscat, Oman) **50**
- RISK MANAGEMENT OF METABOLIC SYNDROME AMONG WORKERS
EXPOSED TO THINNER SOLVENT. INTERVENTION STUDY
Raed M. Alazab, Amal Hegazy, Iman Wahby (Cairo, Egypt) **51**
- INTEGRATED CARE SYSTEM FOR DIABETES MANAGEMENT IN UAE
Saif AlJaibeji (Dubai, United Arab Emirates) **52**
- SIALIC ACID PROFILE IN DIABETIC PATIENTS
Adnan F. Ahmad Alnajjar (Baghdad, Iraq) **53**
- EVALUATION OF SOME MINERALS STATUS INPATIENTS WITH THYROID
GLANDS DISORDERS
F.Ahmad Alnajjar (Baghdad, Iraq) **54**
- BIOCHEMICAL CHANGES IN PSORIASIS
Amina Hamed Alobaidi, Abdulghani Mohamed Alsamara (Tikrit, Iraq) **55**
- GENETIC FACTORS IN OBESITY
Fouad A. Alshaban (Doha, Qatar) **56**
- ROUX-EN-Y GASTRIC BYPASS-ON-VERTICAL BANDED GASTROPLASTY:
8 YEARS EXPERIENCE WITH A MODIFIED GASTRIC BYPASS WICH ENABLES
TRADITIONAL RADIOLOGIC AND ENDOSCOPIC STUDY OF THE FUNCTIONALLY
EXCLUDED STOMACH
Enrico Amenta, Dr. Luca Leuratti, Alessandro Faenza, Dr. Stefano Cariani (Bologna, Italy) **57**
- HYPOGLYCEMIC POTENTIAL OF *CUCURBITA PEPO* L. IN
ALLOXAN-INDUCED DIABETIC RATS
Sedigheh Asgary, Somayeh Kazemi, Jamal Moshtaghian, Mahmood Rafieian
(Isfahan, Iran and Shahrekord, Iran) **58**

POSTER DISCUSSION GROUP A

Abstract # Ref./
Poster Board #

- LIPID LOWERING BY HYDROALCOHOLIC EXTRACTS OF *AMARANTHUS CAUDATUS* L.
INDUCES REGRESSION OF RABBITS ATHEROSCLEROTIC LESIONS
Sedigheh Asgary, Najmeh Kabiri, Hossein Madani, Parvin Mahzouni, Hooman Mirzaalian (Isfahan, Iran) **59**
- EXPRESSION AND LOCALIZATION OF OSTEOACTIVIN IN ALVEOLAR BONE
REGENERATION IN POST-EXTRACTION HEALING SOCKETS IN NORMAL AND
DIABETIC RAT MODEL
Rulla A. Aswad, Mario C. Rico, Steve N. Popoff, Faye Safadi (Philadelphia, PA, USA) **60**
YIA
- CER-001 A NEW GENERATION OF HDL MIMETIC: CHARACTERIZATION AND
DETERMINATION OF IN VITRO AND IN VIVO ACTIVITIES
61
Marine Goffinet, Rudi Baron, Claudine Tardy, Gavin Sy., Anna Schwendeman,
Constance H. Keyserling, John Wetterau, **Ronald Barbaras**, Narendra D. Lalwani,
Jean-Louis H. Dasseux (Labege, France and Ann Arbor, MI, USA)
- EVALUATION OF SMALL-MOLECULE P2Y13 RECEPTOR AGONISTS AS HDL
MODULATORS AND ANTI-ATHEROSCLEROTIC AGENTS
62
Rudi Baron, Marine Goffinet, Nadia Boubekeur, Claudine Tardy, Otto Geoffroy, Anna
Rzepiela, Daniela C. Oniciu, Narendra D. Lalwani, Jean-Louis H. Dasseux,
Ronald Barbaras (Labege, France, Alachua, FL, USA, Delf, Netherlands, and
Ann Arbor, MI, USA)
- HDL AND ABCA1 COOPERATE IN PREVENTING THE CHOLESTEROL-INDUCED
TRANSDIFFERENTIATION OF SMOOTH MUSCLE CELLS TO MACROPHAGE- LIKE CELLS
63
Alessandra Bonomo, Ilaria Giunzioni, Lorenzo Arnaboldi, Alberto Corsini,
Stefano Bellosta (Milan, Italy)
- OBESITY AND SELECTED CO-MORBIDITIES IN A RURAL BANGLADESHI
POPULATION
64
Bishwajit Bhowmik, Faria Afsana, Sanjida Binte Munir, AK Azad Khan, Akhtar Hussain
(Oslo, Norway and Dhaka, Bangladesh)
- GENISTEIN AGLYCONE USE IN METABOLIC SYNDROME: PRELIMINARY
RESULTS FROM A RANDOMIZED CLINICAL TRIAL IN POSTMENOPAUSAL WOMEN
65
Alessandra Bitto, Herbert Marini, Francesca Polito, Rosario D'Anna, Domenica
Altavilla, Francesco Squadrito (Messina, Italy) YIA
- DIFFERENTIAL EFFECTS OF POLYCYSTIC OVARIAN SYNDROME AND OBESITY ON
OXIDATIVE STRESS AND INFLAMMATION
66
Sarah Alison Blair, Tommy Kyaw Tun, Ian S. Young, Niamh A. Phelan, James Gibney,
Jane McEneny (Belfast, United Kingdom and Dublin, Ireland)
- INFLAMMATION AND HDL FUNCTIONALITY: THE ROLE OF OBESITY IN ADOLESCENTS
67
Sarah Alison Blair, Ian S. Young, Liam Murray, Cyril McMaster, Jane McEneny
(Belfast, United Kingdom)
- INVERSE RELATIONSHIP BETWEEN HDL-C RAISING AND HSCRP REDUCTION
IN OLDER PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN AND ATORVASTATIN
68

POSTER DISCUSSION GROUP A

Abstract # Ref./
Poster Board #

- W. Virgil Brown**, JoAnne M. Foody, Franklin Zieve, Charlotte Jones-Burton, Qian Dong, Joanne E. Tomassini, Andrew M. Tershakovec (Atlanta, GA, USA, Boston, MA, USA, Richmond, VA, USA, Rahway, NJ, USA, and N. Wales, PA, USA)
- RELATIONSHIPS BETWEEN HSCRP REDUCTION AND LDL-C, NON-HDL-C, APO B AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN + NIASPAN **69**
- W. Virgil Brown**, Sergio Fazio, John R. Guyton, Qian Dong, Joanne E. Tomassini, Arvind Shah, Andrew M. Tershakovec (Atlanta, GA, USA, Nashville, TN, USA, Durham, NC, USA, Rahway, NJ, USA, and North Wales, PA, USA)
- ANTILIPOLYTIC EFFECTS OF NOVEL NIACIN RECEPTOR (GPR109A) AGONISTS IN RAT AND DOG **70**
- Harm Brummerhop**, Andreas W. Herling, Marcus Korn, Siegfried Stengelin, Guenter Mueller, Ulrich Werner (Frankfurt am Main, Germany)
- OPTIMUM DIET AND CORONARY HEART DISEASE **71**
- Petros Chantzaris** (Athens, Greece)
- IDENTIFICATION OF ADIPOCYTE ANTIGENS THAT ELICIT A HUMORAL IMMUNE RESPONSE IN OBESE QATARI PATIENTS' SERA BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) **72**
- Lotfi Chouchane**, Ravinder Mamtani, Mohammed Al-Thani, Al-Anoud Al-Thani, A. Donny Strosberg, Mouaadh Abdelkarim, Karsten Suhre, Albert Lowenfels, Javaid Sheikh (Doha, Qatar, Jupiter, FL, USA, and Valhalla, NY, USA)
- RISK FACTORS FOR DIABETES AND ITS COMPLICATIONS IN QATAR **73**
- Alvin I. Mushlin, **Paul J. Christos**, Hiam Chemaitelly, Laith J. Abu-Raddad (New York, NY, USA and Doha, Qatar)
- THE TREND OF HYPERTENSION AND ITS RELATIONSHIP TO THE WEIGHT STATUS AMONG TAIWANESE YOUNG ADOLESCENTS **74**
- Nain-Feng Chu** (Taipei, Taiwan)
- ITALIAN LIFE-STYLE AND HEALTH-RELATED BEHAVIORS: PREVALENCE OF PEDIATRIC HYPERTENSION IN A YOUNG POPULATION OF TUSCANY **75**
YIA
- Fommei Costanza**, Franchi Silvia, Coppi Silvia, Strambi Mirella (Siena, Italy)
- BIOAVAILABILITY OF A SINGLE 4G DOSE EPANOVA® (OMEGA-3 FREE FATTY ACIDS) VERSUS LOVAZA® (OMEGA-3-ACID ETHYL ESTERS) WHEN CONSUMED WITH LOW-FAT AND HIGH-FAT MEALS IN HEALTHY ADULTS **76**
- William S. Harris, **Michael H. Davidson**, Judith Johnson, Douglas F. Kling (Sioux Falls, SD, USA, Chicago, IL, USA, and Bedminster, NJ, USA)
- THE ROLE OF CDK-4 IN TYPE-I DIABETES-INDUCED BONE LOSS **77**
YIA
- Fabiola E. Del Carpio-Cano**, Mario C. Rico, Steve N. Popoff, Fayez F. Safadi (Philadelphia, PA, USA)

POSTER DISCUSSION GROUP A

Abstract # Ref./
Poster Board #

- INVESTIGATION OF THE CELLULAR AND MOLECULAR ANTI-INFLAMMATORY RESPONSE IN OBESE INDIVIDUALS SUBJECTED TO A DEFINED EXERCISE PROTOCOL **78**
- Said Dermime**, Jasem Ramadan AlKandari, Fahad Al-Ghimlas, Monira Al-Arouj, Engin Baturcam, Abdullah Bennakhi, Shehab Abdulla Ekrouf, Fatema Hassan, Abdelkrim Khadir, Cynthia Lehe, Ali Tiss, Rasheed Ahmad, Mohammed Dehbi, Amal Hasan (Kuwait, Kuwait)
- INFLUENCE OF CETP, PPARA, APOE AND APOAI POLYMORPHISMS ON HDL-C, APOAI, LPAI AND LPAI:AII CONCENTRATIONS: THE PRIME STUDY **79**
- Hong Quang Do** (Nantes, France)
- DECREASED SERUM 25-HYDROXY VITAMIN D AS A CARDIOVASCULAR RISK FACTOR IN TYPE 2 DIABETIC PATIENTS **80**
- Hisham Salah El-Din El Banawy** (Alexandria, Egypt)
- THE RELATION BETWEEN SERUM LEPTIN, HYPERTENSION, GESTATIONAL DIABETES AND WEIGHT GAIN IN PREGNANT FEMALES **81**
- Hisham Salah El-Din El Banawy** (Alexandria, Egypt)
- CARDIOVASCULAR RISK REDUCTION AT THE WORKPLACE: THE ISRAELI EXPERIENCE **82**
- Dov Gavish**, Chaim Yosephy, J.R Viskoper (Holon, Israel and Ashkelon, Israel)
- THE PREVALENCE OF METABOLIC SYNDROME COMPONENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME, WITHOUT A PREVIOUS DIAGNOSIS OF DIABETES MELLITUS: A PROSPECTIVE STUDY **83**
- Rafid Fayadh Al-Aqeedi, Waleed Khalid Abdulatif, **A. A. Gehani**, Wafer Dabdoob, Abdulbari Bener (Doha, Qatar)
- PREVALENCE OF UNRECOGNIZED DIABETES MELLITUS IN PATIENTS WITH ACUTE CORONARY SYNDROME: A PROSPECTIVE STUDY FROM QATAR **84**
- Waleed Khalid Abdulatif, Rafid Fayadh Al-Aqeedi, **A. A. Gehani**, Wafer Dabdoob, Abdulbari Bener (Doha, Qatar)
- RELATIONSHIP BETWEEN CIRCULATING INFLAMMATORY MARKERS AND IRANIAN POPULATION: FINDINGS FROM ISFAHAN HEALTHY HEART PROGRAM **85**
- Mojgan Gharipour**, Roya Kelishadi (Isfahan, Iran)
- AGE-RELATED EFFECTS OF NIFEDIPINE ON REMOVAL OF CHYLOMYCRON REMNANTS IN MILD HYPERTENSION **86**
- Itamar Grosskopf** (Tel Aviv, Israel)
- PITAVASTATIN HAS NO DETRIMENTAL LONG-TERM EFFECT ON RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (DM) **87**
- Janusz Gumprecht**, Neil Hounslow, Dragos Budinski (Zabrze, Poland and Wokingham, United Kingdom)

POSTER DISCUSSION GROUP A

Abstract # Ref./
Poster Board #

THE NUMBER OF THE COMPONENTS OF METABOLIC SYNDROME IS IN RELATIONSHIP WITH LOW LEVEL INFLAMMATION AND WITH TEETH LOSS IN CARDIO-CEREBROVASCULAR DISEASE Ioan Axente Gutiu , Laurentiu Gutiu, Flavian St Radulescu (Bucharest, Romania)	88
BMI ESTIMATION FROM WAIST MEASUREMENT, NECK CIRCUMFERENCE, MID-UPPER ARM CIRCUMFERENCE and EPWORTH SLEEPINESS SCALE Anwen R. Marshall, Nadim Haboubi , Sian Jones (Llangammarch Wells, United Kingdom, Abergavenny, United Kingdom, Newport, United Kingdom)	89
ZINC SUPPLEMENTATION FOR CONTROLLING INSULIN RESISTANCE AND METABOLIC SYNDROME IN CHILDREN Mahin Hashemipour , Roya Kelishadi, Javad Shapouri (Isfahan, Iran)	90
ANTI-ATHEROGENIC AND ANTI-INFLAMMATORY EFFECTS OF EXTRA VIRGIN OIL: HUMAN INTERVENTION STUDY Olfa Helal , Hicham Berrougui, Abdelouahed Khalil (Sherbrooke, QC, Canada)	91 YIA
PITAVASTATIN HAS A LOW RISK OF DRUG-DRUG INTERACTIONS (DDI): PHARMACOKINETIC STUDIES IN COMBINATION WITH MODULATORS OF CYTOCHROME P450 (CYP) ISOENZYMES AND OATP Neil Hounslow (Wokingham, United Kingdom)	92

Al Wosail Foyer

Posters 93-144

POSTER DISCUSSION GROUP B

Posters marked with YIA are competing for the Young Investigator Award.

Poster Display and Viewing:

Participants may view the Poster Display in the foyer outside the Al Mukhtasar ballroom as follows:

Monday, March 14	5:00 pm – 7:00 pm
Tuesday, March 15	8:30 am – 6:20 pm
Wednesday, March 16	8:30 am – 5:25 pm

Poster Discussion: One of the authors will be available at the poster site as follows:

Poster Discussion Group B (#93-144): Wednesday, March 16	1:00 pm – 2:00 pm
---	-------------------

POSTER DISCUSSION GROUP B

Abstract # Ref./
Poster Board #

CARDIOVASCULAR RISK FACTORS SCREENING, PHYSICAL ACTIVITY AMONG DUBAI POPULATION PREVALENCE AND SOME ASSOCIATED FACTORS Hamid Y. Hussain (Dubai, United Arab Emirates)	93
SMOKING CESSATION OVERVIEW Abdurezag Ahmed Kdesh (Al Ain, United Arab Emirates)	94
THE EFFECT OF LONG STUDYING HOURS AND DIFFERENT LIFESTYLES ON OBESITY AMONG UNIVERSTIY STUDENTS Zainab Azzi Ameen Al Mudamgha, Fatima Khalil (Manama, Bahrain)	95
EFFECTS OF PITAVASTATIN ON HIGH DENSITY LIPOPROTEIN CHOLESTEROL, OTHER LIPOPROTEIN PROFILES AND CHOLESTEROL ESTER TRANSFER PROTEIN IN PATIENTS WITH METABOLIC SYNDROME Sang Hyun Kim , Hyang Lim Lee, Hyun Jae Kang, Hyo Soo Kim (Seoul, South Korea)	96
METABOLIC DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS G. I. Lysenko, L.Ya. Babynina, L.V. Khimion, I.V. Klymas (Kyiv, Ukraine)	97
CLINICAL FACTORS RELATED TO THE SIZE OF CAROTID ARTERIAL PLAQUE IN ACUTE STROKE PATIENTS Jun Hong Lee (Koyang-shi, South Korea)	98
BREAST REDUCTION IN PATIENTS WITH BMI>30 Fedele Lembo , Antonella Campanale, Domenico Parisi, Aurelio Portincasa (Foggia, Italy)	99
ROLE OF THE PARAOXONASE1 (PON1) IN THE ANTI-INFLAMMATORY PROPERTIES OF HDL AGAINST ATHEROSCLEROSIS Soumaya Loued (Sherbrooke, QC, Canada)	100 YIA

POSTER DISCUSSION GROUP B

Abstract # Ref./
Poster Board #

- INCREASE OF OVERWEIGHT AND OBESITY RATES AND THEIR ASSOCIATION WITH DIETARY BEHAVIORS IN SYRIA
Ellina Lytvyak, Khaldoun Alassad (New Orleans, LA, USA) **101**
YIA
- OBESITY IN THE QATARI POPULATION: PUBLIC HEALTH AND GENOMIC PERSPECTIVES
Ravinder Mamtani, Albert Lowenfels, Mohammed Al-Thani, Al-Anoud Al-Thani, A. Donny Strosberg, Mouaadh Abdelkarim, Karsten Suhre, Javaid Sheikh, Lotfi Chouchane (Doha, Qatar, Surgery, Valhalla, NY, USA, Jupiter, FL, USA) **102**
- TARGETING ENDOTHELIAL NITRIC OXIDE SYNTHASE FOR THE TREATMENT OF DIABETIC VASCULAR DISEASE
Chris R. Triggler, Sadeer Al Kindi, Dhritiman Gurkha, Srihari Buddhavarapu, Salman Al Jerdi, Rahima Sanya, Yahya Al Mezrakchi, **Isra Marei**, Fatiha Bensilmane, Gnanapragasam Arunachalam, Hong Ding (Doha, Qatar) **103**
- COMPARISON OF THE EFFECTS OF LOW-CARBOHYDRATE HIGH-FAT & HIGH-CARBOHYDRATE LOW-FAT WEIGHT-REDUCTION DIETS ON LIPOPROTEIN SUBFRACTIONS IN OVERWEIGHT & OBESE SUBJECTS
Jane McEneny, Peter AC McPherson, Michelle Spence, Una Bradley, Michelle McKinley, Ian S. Young, Steven Hunter (Belfast, United Kingdom) **104**
- CELL THERAPY FOR THE FUTURE TREATMENT OF DIABETES
Laila Mahmoud Montaser, Sherine Mohamed Fawzy (Shebin El-Kom, Egypt and Cairo, Egypt) **105**
- STATINS POTENTIALLY INDUCE AUTOPHAGY AND CELL DEATH IN HUMAN RHABDOMYOSARCOMA CELLS BY DEPLETING GERANYLGERANYL DIPHOSPHATE
Kiyoto Motojima, Makoto Araki (Tokyo, Japan and Iwate, Japan) **106**
- MICROVESICLES HARBOURING GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS AND RNA CONTROL LIPID SYNTHESIS BETWEEN LARGE AND SMALL ADIPOCYTES
Günter Müller, Susanne Wied, Marion Schneider (Frankfurt am Main, Germany) **107**
- REMNAINT-TG AS A THERAPEUTIC TARGET FOR LOWERING PLASMA TRIGLYCERIDES
Katsuyuki Nakajima, Takamitsu Nakano, Akira Tanaka (Gunma, Japan and Tokyo, Japan) **108**
- PSYCHOLOGICAL ASPECTS OF NEURO-ENDOCRINE DISTURBANCES & METABOLIC SYNDROME: STRESS RELATED PROBLEMS IN UNVERISTY STUDENTS, AND THE USE OF CONVENTIONAL AND ALTERNATIVE MEDICAL TREATMENTS
Zainab Azzi Ameen Al Mudamgha, **Hussain Nezar** (Manama, Bahrain) **109**
- EVALUATION OF SERUM TOTAL CHOLESTEROL AND TRIGLYCERIDE LEVELS IN RURAL AND URBAN DWELLERS
Zeribe Chike Nwosu, Eucharia Mma Oti (Jaba L.G.A, Nigeria) **110**
YIA

POSTER DISCUSSION GROUP B

Abstract # Ref./
Poster Board #

- INFERTILITY: A NIGERIAN PERSPECTIVE
Zeribe Chike Nwosu (Jaba L.G.A, Nigeria) **111**
- DIET-INDUCED OBESITY CAUSES HEPATIC OXIDATIVE STRESS: MECHANISMS AND INTERVENTION
Karmin O (Winnipeg, MB, Canada) **112**
- PHOSPHORUS PRELOAD SUPPRESSES SUBSEQUENT ENERGY INTAKE THROUGH SATIATION NOT SATIETY
Omar Obeid, Sara Dimachkie, Sani Halis (Beirut, Lebanon) **113**
- ARTERIAL RIGIDITY ESTIMATED BY 24-HOURS MONITORING OF THE BLOOD PRESSURE AND ECG IN ELDERLY
Valentin Oleynikov, Lyudmila Gusakovskaya, Nadezhda Sergatskaya (Penza, Russia) **114**
- THE ASSESSMENT OF COMPLEX TREATMENT INFLUENCE'S OF METABOLIC SYNDROME WITH HYPERTENSION 1-2 DEGREES ON THE BLOOD PRESSURE AND THE STRUCTURAL AND FUNCTIONAL ARTERIAL PROPERTIES
Irina Matrosova, Irina Eliseeva, **Valentin Oleynikov** (Penza, Russia) **115**
- BENEFITS OF SINGLE-PILL AMLODIPINE/ATORVASTATIN FOR CARDIOVASCULAR RISK REDUCTION IN SLOVAKIA: THE STRONG DUET STUDY
Daniel Pella, Jan Fedacko, Rafael Rybar (Kosice, Slovakia) **116**
- BLACK AFRICANS WITH HYPERLIPIDAEMIA HAVE A HIGH PREVALENCE OF TYPE 2 DIABETES AND THE METABOLIC SYNDROME BUT ARE BEING INADEQUATELY TREATED FOR THEIR HYPERLIPIDAEMIA - RESULTS FROM THE CEPHEUS SA STUDY
Frederick Raal, Colin Schamroth, Guy Vandenhoven, Anne-Marie Temmerman (Johannesburg, South Africa and Zaventem, Belgium) **117**
- BARIATRIC SURGERY EXPERIENCE OF THE UNIVERSITY HOSPITA ÖREBRO AND LINDESBERG 2000-2010 SWEDEN
Mustafa Raouf (Örebro, Sweden) **118**
- PROTECTIVE EFFECT OF L-ARGININE IN EXPERIMENTALLY INDUCED MYOCARDIAL ISCHEMIA: COMPARISON WITH ASPIRIN
Alaaeldin Ismail Saleh, Mohamed Zakria Gad, Sahar Mohamed Abdel Maksoud, Shohda Assem El-Maraghy (Cairo, Egypt) **119**
- ACYLATION STIMULATING PROTEIN PLASMA LEVELS ARE STRONGLY PREDICTED BY WAIST/HIP RATIO AND CORRELATE WITH ATHEROGENIC RISK FACTORS IN OMANI MALES
Jumana Saleh, Rabab A. Wahab, Katherine Cianflone (Muscat, Oman, Manama, Bahrain, and Laval, QC, Canada) **120**

POSTER DISCUSSION GROUP B

Abstract # Ref./
Poster Board #

- CHOLESTEROL LOWERING EFFECT OF SAR236553/REGN727 IN HAMSTER AFTER SINGLE S.C. INJECTION **121**
Hans Ludwig Schaefer, Eugen Falk, Andreas W. Herling, Uwe Schwahn, Mark W. Sleeman, Hartmut Rütten (Frankfurt, Germany)
- DEVELOPMENT AND IMPLEMENTATION OF A EUROPEAN PRACTICE GUIDELINE AND TRAINING STANDARDS FOR DIABETES PREVENTION – THE IMAGE PROJECT – IMPLICATION FOR THE GULF STATES **122**
Jacqueline Schwarz (Dresden, Germany)
- HEALTHY-LIFESTYLE APPROACH TO WEIGHT MANAGEMENT **123**
Timothy D. Shaw, **Habiba N. Shaw** (Eufaula, AL, USA)
- REGULATORY EFFECT OF DECURSIN ON SPHINGOSINE KINASE ACTIVITIES IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS **124**
Dr. Kyong-Oh Shin, Myung-Yong Park, Hwan-Soo Yoo, Sei-Kwan Oh, Dr. Hyun-Seok Lee, Yong-Hyeon Yim, Yong-Moon Lee (Cheongju, South Korea)
- A Naturalistic Assessment of the Change in Lipid Fractions between Patients Continuing Moderate Dose Statin Monotherapy or Augmenting with Niacin Extended-Release **125**
Robert J. Simko, Rebecca A. Cobb, Ralph A. Quimbo, Mark J. Cziraky (Abbott Park, IL, USA and Wilmington, DE, USA)
- Change in Lipid Fractions and Goal Attainment Following the Initiation Moderate Dose Statin Monotherapy and Subsequent Augmentation with Niacin Extended-Release **126**
Robert J. Simko, Rebecca A. Cobb, Ralph A. Quimbo, Mark J. Cziraky (Abbott Park, IL, USA and Wilmington, DE, USA)
- DIABETOGENIC EFFECT OF VARIOUS LIPID ABNORMALITIES IN ASIAN INDIAN POPULATION; THE CHENNAI URBAN RURAL EPIDEMIOLOGY STUDY **127**
Brijendra Kumar Srivastava, M. Deepa, Mohan V (Chennai, India)
- PROJECT OF HEALTH SUPPORT FOR OBESE PATIENTS WITH DM II TYPE – CHANGES OF SERUM LIPIDS LEVEL **128**
YIA
Hana Stritecka, Pavol Hlubik (Hradec Kralove, Czech Republic)
- PROJECT OF HEALTH SUPPORT FOR OBESE PATIENTS WITH DM II. TYPE – CHANGES OF SERUM LIPIDS LEVEL **129**
YIA
Hana Stritecka, Pavol Hlubik (Hradec Kralove, Czech Republic)
- INVESTIGATING THE GENETICS OF CORONARY ARTERY CALCIFICATION IN PROFESSIONAL FIREFIGHTERS **130**
H. Robert Superko, Thomas White, David A. Ross, John Sninsky, Brenda C. Garrett, Steve Frowhein, FACC, Lakshmana Pendyala, Steve Rolader (Alameda, CA, USA, Portola Valley, CA, USA, Atlanta, GA, USA, Louisville, KY, USA, and Lawrenceville, GA, USA)

POSTER DISCUSSION GROUP B

Abstract # Ref./
Poster Board #

- THE METABOLIC SYNDROME PREDICTS ATHEROSCLEROSIS IN PROFESSIONAL FIREFIGHTERS WHILE STANDARD LIPIDS AND BMI DO NOT **131**
H. Robert Superko, Thomas White, Brenda C. Garrett, Steve Frowhein, Lakshmana Pendyala, Spencer King III, Kathryn M. Momary (Alameda, CA, USA, Portola Valley, CA, USA, Atlanta, GA, USA, and Louisville, KY, USA)
- CARDIOVASCULAR SCREENING USING EXERCISE STRESS ECHOCARDIOGRAPHY IN OBESE PATIENTS UNDERGOING BARIATRIC SURGERY **132**
Wadea M. Tarhuni, Sajid Khan, Ghazala Shamim, Martin S. Lubanski (Windsor, ON, Canada)
- WOMEN WITH PCOS HAVE SIGNIFICANTLY LOWER LEVEL OF CIRCULATING APELIN: A NOVEL CLINICAL EVIDENCE FOR INVOLVEMENT IN THE REGULATION OF INSULIN SENSITIVITY? **133**
Erdem Ercan, **Ilker Tasci**, Seyit Temel Ceyhan, Serkan Tapan, Teoman Dogru, Gokhan Ozgur, Gurkan Celebi, Gokhan Erdem (Ankara, Turkey)
- INSULIN RESISTANCE VALUES IN NORMAL WEIGHT VEGETARIANS AND NON-VEGETARIANS **134**
YIA
Martina Valachovicova, Marica Krajcovicova- Kudlackova, Katarina Babinska, Viera Spustova, Pavel Blazicek, Csilla Mislanova, Jana Malekova (Bratislava, Slovakia)
- DIETARY IRON OVERLOAD INDUCES VISCERAL ADIPOSE TISSUE INSULIN RESISTANCE ASSOCIATED WITH HYPER-RESISTINEMIA, AND SYNERGIZES WITH OBESITY IN INDUCING SYSTEMIC INSULIN RESISTANCE **135**
YIA
Paola Dongiovanni, Massimiliano Ruscica, Luca Benedan, Vittorio Borroni, Stefania Recalcati, Liliana Steffani, Stefano Gatti, Flavio Caprioli, Gaetano Cairo, Paolo Magni, Silvia Fargion, **Luca Valenti** (Milano, Italy)
- ADDITIVE EFFECTS OF NIACIN ON TOP OF SIMVASTATIN TREATMENT IN REDUCING ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP MICE **136**
YIA
José W.A. Van der Hoorn, Susan Jordaan, Mieke Louwe, Johannes W.A. Smit, Louis M. Havekes, Patrick C.N. Rensen, Hans M.G. Princen, J. Wouter Jukema (Leiden, Netherlands)
- ALISKIREN INHIBITS ATHEROSCLEROSIS DEVELOPMENT AND IMPROVES PLAQUE STABILITY IN APOE*3LEIDEN.CETP TRANSGENIC MICE WITH OR WITHOUT TREATMENT WITH ATORVASTATIN **137**
S Kühnast, **José W.A. Van der Hoorn**, AM van den Hoek, LM Havekes, G Liau, JW Jukema, HMG Princen (Leiden, Netherlands and Cambridge, MA, USA)
- IN VIVO* ANALYSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN A TRANSLATIONAL MODEL FOR THE METABOLIC SYNDROME **138**
YIA
José W.A. Van der Hoorn, Roland A. Molengraaf, Rami Nachabe, Marijn L. Vlaming, Charles F. Sio, Rolf Lamerichs, Jeroen DeGroot, Oliver C. Steinbach (Leiden, Netherlands, Eindhoven, Netherlands, and Zeist, Netherlands)

POSTER DISCUSSION GROUP B

Abstract # Ref./
Poster Board #

- LOW DOSE OF LXR AGONIST AZ876 REDUCES ATHEROSCLEROSIS IN
APOE*3LEIDEN MICE WITHOUT AFFECTING LIVER OR PLASMA
TRIGLYCERIDE LEVEL **139**
José W.A. Van der Hoorn, Daniel Lindén, PhD, Ulrika Lindahl, Marian E.A. Bekkers,
Marijke Voskuilen, Ralf Nilsson, Jan Oscarsson, Eva-Lotte Lindstedt, Hans M.G. Princen (Leiden,
Netherlands and Mölndal, Sweden)
- ENDOCRINE ACTIVITY OF ADIPOSE TISSUE IN PATIENTS WITH METABOLIC
SYNDROME. **140**
Kateryna Yanovska (Kyiv, Ukraine)
- ENHANCED PLATELET AGGREGATION, HYPERINSULINEMIA AND LOW
TESTOSTERONE LEVEL IN MONOSODIUM GLUTAMATE OBESE RATS **141**
Magda Hassanein Youssef (Cairo, Egypt)
- MANIFESTATION OF METABOLIC SYNDROME IN WOMEN WITH
PROLACTINOMA **142**
Tatyana Alexeevna Zykova, Lydmila Sergeevna Pavlova, Ilia Nicolaevich Zykov
(Arhangelsk, Russia)
- MODULATIONS OF METABOLISM AND REPRODUCTIVE FUNCTION IN
WOMEN WITH POLYCYSTIC OVARIAN SYNDROME AND INCREASED BODY
WEIGHT WHEN USING TAURIN **143**
T.A. Zykova, Alexandra Vitalievna Strelkova, Lidya Vladimirovna Uledeva,
Ilia Nicolaevich Zykov (Arhangelsk, Russia)
- SPERM PATHOLOGY IN MEN WITH METABOLIC SYNDROME **144**
Tatyana Alekseevna Burmistrova, **T.A. Zykova**, I.N. Zykov, A.V. Dobryzhenkov
(Arkhangelsk, Russia)



www.dalm2011qatar.org